SCHEMBL15377682

SCHEMBL15377682

CN1CCN(c2ccc(Nc3ncc4c(n3)-c3c(c(C(=O)O)nn3C)CCC4)cc2)CC1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTK P33981 5/20 0.85
▸ PIM1 P11309 2/20 0.85
▸ PIM2 Q9P1W9 2/20 0.85
▸ CDK2 P24941 15/20 0.76
▸ CCNA2 P20248 11/20 0.76
▸ AURKA O14965 9/20 0.76
▸ CDK4 P11802 7/20 0.76
▸ CDK6 Q00534 7/20 0.76
▸ CCND3 P30281 6/20 0.76
▸ CCNA1 P78396 5/20 0.68
▸ PLK1 P53350 3/20 0.68
▸ GAK O14976 1/20 0.59
▸ BUB1 O43683 1/20 0.59
▸ CCNT1 O60563 1/20 0.59
▸ ULK1 O75385 1/20 0.59
▸ STK16 O75716 1/20 0.59
▸ PRKD3 O94806 1/20 0.59
▸ LATS1 O95835 1/20 0.59
▸ ABL1 P00519 1/20 0.59
▸ EGFR P00533 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12698351 0.92 TTK (1.00) TTKPIM1PIM2CDK2CCNA2
Trifluoroacetic Acid SCHEMBL15377924 0.89 TTK (0.90) TTKPIM1PIM2CDK2CCNA2
SCHEMBL12698166 0.89 TTK (0.79) TTKPIM1PIM2CDK2CCNA2
SCHEMBL15385485 0.88 TTK (0.77) TTKPIM1PIM2CDK2CCNA2
Hydrochloric Acid SCHEMBL12499339 0.87 TTK (0.76) TTKPIM1PIM2CDK2CCNA2
SCHEMBL12698391 0.86 TTK (0.74) TTKPIM1PIM2CDK2CCNA2
SCHEMBL15377867 0.85 TTK (0.68) TTKPIM1PIM2CDK2CCNA2
SCHEMBL4166117 0.85 CDK2 (1.00) TTKPIM1PIM2CDK2CCNA2
SCHEMBL12698401 0.85 TTK (0.77) TTKPIM1PIM2CDK2CCNA2
SCHEMBL15377577 0.84 TTK (0.71) TTKPIM1PIM2CDK2CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2668188-B1 TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-05-18 — — EP disclosed
US-8916577-B2 Tricyclic derivatives, process for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-12-23 — — US disclosed
US-20130302416-A1 TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-11-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130302416-A1 TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS CDK1, MAP3K1, MAP3K20 TTK 223/4885PIM1 715/4885PIM2 726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback